Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Provided By GlobeNewswire
Last update: Feb 5, 2025
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data --
Read more at globenewswire.com30.65
+1.53 (+5.25%)
Find more stocks in the Stock Screener
PCVX Latest News and Analysis
19 days ago - ChartmillTop stock movements in today's session.Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
19 days ago - ChartmillMonday's session: top gainers and losersHere are the top movers in Monday's session, showcasing the stocks with significant price changes.
20 days ago - ChartmillThese stocks are gapping in today's sessionTraders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
20 days ago - ChartmillMonday's pre-market session: top gainers and losersBefore the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
